Short answer
SELLAS Life Sciences Group, Inc. (SLS) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
SELLAS Life Sciences Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Corporate update furnished in Exhibit 99.1
- Investor focus: reported financial results and development updates in the press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $9.6M, or $0.05 per share, versus $6.6M and $0.07 in Q2 2025
- Cash $138.3M at June 30, 2026, supporting GPS REGAL analysis and SLS009 clinical development
- GPS Phase 3 REGAL trial nearing its prespecified 80th event, triggering final analysis and potential FDA BLA submission
- SLS009 Phase 2 frontline AML trial enrolled 28 of 80 patients, with topline data expected in Q4 2026
- R&D expense rose to $6.3M from $3.9M as manufacturing, trial, regulatory, and potential BLA preparation costs increased
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SELLAS Life Sciences Group, Inc. 8-K filings
Get the next SLS 8-K as it lands
Follow SLS for push alerts, or ask the research agent what this filing means.